FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.